Precision-cut liver slices as a model for the evaluation of host-targeting agents against hepatitis B and delta viruses https://t.co/wWeF3gVoho #biorxiv_micrbio
We look forward to receiving your contributions to the special issue "Cellular Immune Response to Hepatitis Viruses".
Deadline : 31 January 2026
#livertwitter
https://t.co/6npc1DEnO9
Studies with Tocilzumab in humans reveal that post-meal, IL-6 activity promotes the storage of meal-derived fatty acids in subcutaneous fat and increases the escape of meal-derived fatty acids into the bloodstream https://t.co/CBj9Z3H5KM @CellRepMed
📢 New Research Alert! 🚀
🏥Protein tyrosine phosphatase delta is a STAT3-phosphatase and suppressor of metabolic liver disease
🔬 New findings reveal that hepatic PTPRD expression is associated with signaling pathways regulating glucose and lipid metabolism, highlighting its key role in metabolic liver disease. #LiverDisease #Metabolism #STAT3 #Hepatology #MedicalResearch
📖 Read more: https://t.co/YBbq3AwKbI
@Gut_BMJ@BMJ_Open@FrontGastro_BMJ
💡Don't miss this perspective in eGastroenterology!💡The perspective, “New dimension in viral hepatitis research” by Massimiliano Cocca and Barbara Testoni from the INSERM U1052, CNRS UMR-5286, Cancer Research Center of Lyon, interprets a proof-of-concept study demonstrates the feasibility of spatial transcriptomics in analysing HBV infections.🔍📖#HepatitisB #SpatialTranscriptomics #HBV #LiverResearch
🔗https://t.co/9qHKHNSsNo
@Gut_BMJ@BMJ_Open@FrontGastro_BMJ
🚨 New paper out! 🚨
We show how hepatitis B virus (HBV) mRNA can be detected in single-cell RNA sequencing without prior knowledge or specific amplification.
📄 Read here: https://t.co/PWsjGXJGvH
🔬 Code: https://t.co/V6aTtFbz5c
#HBV#scRNAseq#Virology#Bioinformatics
Extrahepatic complications of MASLD: cause or association? It depends on:
👉🏼 Genetic background
👉🏼 MASLD severity - increasing insulin resistance & risk of T2DM
👉🏼 Other cardiometabolic risk factors
#SLDsummit state-of-the-art by Cyrielle Caussy @IHU_HepatoLyon@EASLnews
Spatial multi-omics has just gone to the next level!
https://t.co/joA2nhNgqE
https://t.co/ZTIt1gAu5l
—Integration of 5 omic modalities w/ spatial resolution at 20 -50 μm
—"a new era for characterizing tissue & cellular heterogeneity that single-modality studies alone could not reveal"
Making space for spatial biology in the clinic
Spatial transcriptomics methods have been slow to move into clinical practice, but spatial proteomics are cheaper and more scalable, and could progress faster https://t.co/0ff7OMxexN
📢📢 POST-DOC JOB VACANCY 📢📢
We're currently hiring for a Post-Doctoral Scientist to join our Liver-Brain Axis group 🧠 working on "Understanding the Mechanisms underlying the Detrimental Effects of MASLD on the Brain" 👩🔬🧫
Follow the link below for more info and to apply today!
https://t.co/ZRZ4mrpHC9
#ScienceCareers #STEMcareers #PostDoc #PostDoctoral #LiverTwitter #LiverResearch #Hepatology #LiverBrainAxis
@AHadjihambi @phil_newsome7@f4liverresearch@kingsmedicine@KCLImmunoMicro@KingsCollegeNHS@KingsCollegeLon
🆕Article in press❕
Differential HBV RNA and HBcrAg patterns in untreated patients with chronic hepatitis delta
Read it here👉https://t.co/ojLNcqEQlX
#LiverTwitter
📌In our December issue
Hepatitis B virus DNA integration
➡️Implications for diagnostics, therapy, and outcome
#OpenAccess here👉https://t.co/sGhVisafY5
@FabienZoulim
#LiverTwitter
Watch the latest #GUTVideo from the paper by Roca Suarez @andresroca et al entitled
"TLR8 agonist selgantolimod regulates Kupffer cell differentiation status and impairs HBV entry into hepatocytes via an IL-6-dependent mechanism" via
https://t.co/7gJeGSNcSf
Paper via: https://t.co/CX4Lra7cc2
@ipcureb @IHU_HepatoLyon @TestoniResearch @FabienZoulim @MPlissonnier #HBV
Watch the latest #GUTVideo from the paper by Roca Suarez @andresroca et al entitled
"TLR8 agonist selgantolimod regulates Kupffer cell differentiation status and impairs HBV entry into hepatocytes via an IL-6-dependent mechanism" via
https://t.co/7gJeGSNcSf
Paper via: https://t.co/CX4Lra7cc2
@ipcureb @IHU_HepatoLyon @TestoniResearch @FabienZoulim @MPlissonnier #HBV
Drs. Harry L.A. Janssen and Milan J. Sonneveld describe the science behind a clinical trial of a combination of therapies, including xalnesiran, to treat chronic hepatitis B virus infection. Read the full editorial: https://t.co/5MvQYbJmtT